Host Cell Protein (HCP) Assay Performance Data To Be Presented

CAMBRIDGE, MA – BioScale Inc., an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, will unveil the ViBE™ Protein Analysis Workstation at the BioProcess International Conference September 21-23, 2010 in Providence, RI, booth number 916. In addition, the results of a comparison study conducted by Millipore

Corporation measuring the concentration of Chinese Hamster Ovary (CHO) HCP contaminants in 102 bioprocess samples will be presented in a poster session on Wednesday, September 22, from 12-2:30 PM. The poster is entitled: “Performance of the BioScale ViBE™ Workstation Host Cell Protein Assay.”

“The pharmaceutical industry is rapidly changing its emphasis from purely small molecule drugs to a blend of small molecule and protein based therapeutics,” commented Chip Leveille, BioScale’s Chief Operating Officer. “As more biologic drugs are introduced into the pipeline, the industry will need to retool its quality control and production processes. We believe BioScale’s ViBE platform is ideally suited for the growing needs of the pharmaceutical industry to provide world-class protein measurement within an easy-to-use workstation format.”

According to a report issued in May 2010 by the Biotechnology Industry Organization, there are currently more than 200 FDA-approved biologic therapies and vaccines with more than 600 others in the development pipeline. The need to assure product safety and quality by biopharma companies necessitates better tools to ensure that impurities and titer are analyzed quickly and accurately. The ViBE Workstation is a powerful new productivity tool capable of performing several important BioProcess applications including Host Cell Protein assays, Protein A residual contaminant and product titer analysis — all on one platform. Combining traditional assay formats with proprietary detection technology, the ViBE enables higher quality results, faster assay development and improved process

workflow with limited manual intervention.

Powered by AMMP™ Technology, the ViBE platform enables advancements in protein research. AMMP (Acoustic Membrane MicroParticle) technology is a unique mechanical integration of magnetic microparticles, a universal sensor and acoustic science delivering a proprietary, non-optical protein detection and quantitation technique that is highly robust and versatile, with ease of methods transfer from traditional assay formats. The ViBE Workstation is the ideal tool for reliable, unattended sample analysis including reagent additions, incubation and real-time results with walkaway operation and is well suited for a variety of applications including bioprocess engineering and manufacturing assays and biomarker discovery and development.

ViBE Protein Analysis Workstations are currently being used by major pharmaceutical and biotech companies and in world-renowned research institutes to perform a wide range of protein analysis applications not only with more sensitive, reproducible data, but with the power to work in complex samples more quickly and efficiently than ever before. For more information or to get a copy of the poster presentation contact info@bioscale.com, call 617- 301-6000, or visit the company’s website at www.bioscale.com.

About BioScale

BioScale is a life science company that develops, manufactures and promotes a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE platform enables highly-sensitive detection and quantitation of proteins in complex samples used in preclinical and clinical research, bioprocess, patient point-of-care and personalized medicine applications. Founded in 2002, the Company is headquartered in Cambridge, MA. For more information, visit www.bioscale.com.

Forward Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding BioScale’s future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company’s ability to obtain financing, the development and commercialization of ViBE systems, the prospects of the Company’s protein analytics platform, the Company’s strategies to develop and commercialize protein analytics systems and the breadth of the Company’s technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is

planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. BioScale is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

BioScale logo, AMMP and ViBE are trademarks of BioScale, Inc.